INTRODUCTION

Coronavirus disease 2019 (COVID-19), a deadly disease induced by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first discovered in China, and is accompanied by a high degree of morbidity and mortality [1]. The virus has spread across the world and infected very large populations, especially in the United States [2]. Clinical features of COVID-19 may include pyrexia, asthenia, dyspnea, as well as acute respiratory distress syndrome, septic shock, and coagulation dysfunction in critically ill patients [3]. It is believed that, due to its high fatality rate, SARS-CoV-2 may strongly bind to angiotensin-converting enzyme 2 (ACE2), which is a key factor in the pathological pathway of SARS-CoV infection in the host [4]. The latest research findings have indicated that the affinity of SARS-CoV-2 to ACE2 may be 10 to 20 times greater than that of SARS-CoV [5]. In the SARS-CoV-2-infected population, it has been reported that people aged over 65 years have the highest rate of death [6]. Clinically, an effective and accurate diagnosis of SARS-CoV-2 has been achieved. However, the medical pharmacotherapy to treat COVID-19 is still insufficient...
Accordingly, it is necessary to explore and develop bioactive compounds to treat COVID-19. Vitamins are considered as a food supplement and have been reported to play an important role in the immune system [8]. Vitamin A (VA) has potent physiological functions, such as promoting growth and reproduction and maintaining bone, epithelial tissue, vision, and normal secretion of mucosal epithelium. VA and its derivatives can prevent precancerous lesions [9]. An increasing number of reports indicate that VA is necessary to maintain immune function and that it is responsible for immune cell differentiation and proliferation [10]. It has been reported that VA can improve the ability of immune cells to produce antibodies and induce T lymphocytes to release functional lymphokines through modulation of target genes via nuclear receptors [11]. Additionally, VA is extremely important for maintaining sufficient levels of natural “killer cells” (showing antiviral activity) in circulating blood [12]. VA adjuvant therapy may enhance body immune function by increasing IgM and IgG levels and activating T lymphocytes [13]. More importantly, vitamin A was reported to play a significant role against pneumonia. It is evidenced that low VA content is linked to neonatal pneumonia [14]. Clinical data show that VA deficiency is implicated in fatal mycoplasma-induced pneumonia in children [15]. In addition, VA supplementation contributes to the reduction of clinical complications and shortening of in-hospital time for children with pneumonia [16]. All these pieces of evidence suggest that vitamin A may be an optional treatment for COVID-19; however, to date there has been no investigation of VA against SARS-CoV-2, especially its pharmacological mechanism. In this report, we aimed to determine and identify the curative effect of VA for treating COVID-19 and to utilize a network pharmacology approach to uncover the mechanisms underlying the therapeutic role of VA.

RESULTS

Identification of SARS-CoV-2- and vitamin A-associated genes

In order to determine the SARS-CoV-2-associated and VA-pharmacological action genes, we conducted a series of bioinformatic analyses. We assayed and identified 393 SARS-CoV-2-associated genes from the Genecard and OMIM datasets. In addition, 122 VA-pharmacological action genes were identified following data correction using the UniProt tool (Figure 1). When we compared the target (VA-associated and SARS-CoV-2-associated) genes, 15 VA-associated targets against SARS-CoV-2 were identified, and the common genes were subjected to target-function-protein interaction network analysis (Figure 1). By setting the median degree of freedom to 2.923, the maximum degree

Figure 1. Identification of vitamin A and SARS-CoV-2 associated genes. Venn diagram showing the intersection targets of vitamin A against SARS-CoV-2 with an identified PPI network.
of freedom to 7, and the core target screening condition ranged to 3–7), seven core targets of VA against SARS-CoV-2 were identified, namely MAPK1, IL10, EGFR, ICAM1, MAPK14, CAT, and PRKCB (Figure 2).

**Biological role of vitamin A against SARS-CoV-2**

The core targets were subjected to gene ontology (GO) biological process and KEGG pathway enrichment analysis to understand the possible biological role of VA and the signaling pathway against SARS-CoV-2. The GO results highlighted that VA mediated a number of biological processes related to cellular response to the virus, immunity, cytokine production and secretion, and inflammatory response (Figure 3A and Supplementary Table 1). Immune responses are mediated by different classes of immune cells, such as neutrophils and lymphocytes, through the immune response-activating cell surface receptor signaling pathway. The VA-mediated immune response is also regulated by immunoglobulin production (Figure 3A and Supplementary Table 1). In addition, VA played a role in both acute and chronic inflammatory responses against SARS-CoV-2 (Figure 3A and Supplementary Table 1).

**Vitamin A-mediated signaling pathway and network against SARS-CoV-2**

We conducted a KEGG pathway analysis to further understand the possible mechanism underlying the anti-SARS-CoV-2 role of vitamin A. Our results highlighted that vitamin A might regulate a series of signaling pathways related to viral infections, such as human cytomegalovirus, influenza A, Kaposi sarcoma-associated herpes virus, human immunodeficiency virus 1, hepatitis C, Epstein-Barr, and human papilloma virus (Figure 4 and Online Resource 2). In addition, we also found that vitamin A was involved in many important cell signaling pathways such as FoxO, VEGF, TNF, Ras, nuclear factor kappa B (NF-κB), phospholipase D, mTOR, and JAK-STAT (Figure 4 and Supplementary Table 2). More importantly, we found the involvement of vitamin A in immune responses such as T cell receptor signaling pathway, leukocyte transendothelial migration, natural killer cell mediated cytotoxicity, Fc epsilon RI signaling pathway, B cell receptor signaling pathway, Th1 and Th2 cell differentiation, Fc gamma R-mediated phagocytosis, IL-17 signaling pathway, Toll-like receptor signaling pathway, Th17 cell differentiation, and human T-cell leukemia virus 1 infection (Figure 4 and Supplementary Table 2). Vitamin A regulates cytokine production via NOD-like receptor signaling pathway and chemokine signaling pathway (Figure 4 and Supplementary Table 2). These findings suggest that vitamin A could be a potential treatment for COVID-19. Finally, we used Cytoscape software to construct the gene network diagram of VA-target-GO-KEGG-SARS-CoV-2 (Figure 5).
Figure 3. Gene ontology analysis of the seven core targets of vitamin A against SARS-CoV-2. (A) Bubble diagram showing the vitamin A-mediated biological process against SARS-CoV-2. (B) All core biotargets of vitamin A against SARS-CoV-2 were linked to the top 10 most enriched GO terms in Circro diagrams.
Figure 4. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of the seven core targets of vitamin A against SARS-CoV-2. (A) Bubble diagram showing the vitamin A-mediated cell signaling pathways against SARS-CoV-2. (B) Identified core biotargets of vitamin A against SARS-CoV-2 were associated with the 10 most enriched KEGG terms in Circro diagrams.
Figure 5. Interaction network of the target-KEGG pathways of VA against SARS-CoV-2. The middle part represented the anti-SARS-CoV-2 targets of vitamin A, and the enriched top 20 biological functions and KEGG pathways.
DISCUSSION

Recently, the prevalence and mortality of SARS-CoV-2 has increased sharply worldwide, especially in developed countries in 2020 [17]. However, there are few existing drug treatments for COVID-19, and some of the immunotherapy treatments and antiviral drugs used in clinical practice have shown limited therapeutic effectiveness [18]. Thus, further investigation and development of potential therapeutic agents is warranted. In this bioinformatics report, we aimed to identify and reveal the anti-SARS-CoV-2 targets and molecular mechanisms of VA through an emerging approach to network pharmacology. VA may exert potent, beneficial pharmacological activity for the treatment of COVID-19 via associated cytoprotection, anti-viral and anti-inflammatory effects, and immunoregulation. By using the network pharmacology strategy to uncover the molecular functions, the anti-SARS-CoV-2 effects of VA could be shown to be modulated by some key molecules and corresponding genes, including MAPK1, IL10, EGFR, ICAM1, MAPK14, CAT, and PRKCB. In our previous report, we demonstrated that vitamin C could also modulate a cluster of core targets against SARS-CoV-2 [19]. When we compared the findings, we found that two core targets, MAPK1 and EGFR, were found in the effect of both vitamin A and vitamin C. MAPK1, a functional protein kinase, is a key connection in the switch from extracellular irritation to intracellular signaling. Changes in the signaling pathway are evidenced in complex diseases, including cancers [20]. It has been reported that anti-pneumonia action exerted by VA is related to specific suppression of the MAPK signaling pathway, including MAPK1 activity [21]. EGFR, a tyrosine kinase receptor, plays important roles in modulating cell proliferation, division, differentiation, survival, and oncogenesis [22]. It has been reported that EGFR-mutated patients are likely to have hospital-acquired pneumonia [23]. IL-10, a pivotal anti-inflammatory cytokine, can effectively control inflammatory Th cells and immunopathology and secure cellular homeostasis [24]. Some reports have shown that inactivation of IL-10 is linked to an increased risk of developing pneumonia [25–26]. ICAM-1, a transmembrane glycoprotein receptor, can

![Figure 6. A schematic diagram to summarize the workflow of the study.](image-url)
recruit inflammatory cells and cytokines to target tissue [27]. Reportedly, blood ICAM-1 content may function as a potent biomarker of patients with pneumonia [28], including pediatric pneumonia [29]. Catalase, a well-known antioxidant enzyme, acts as an oxidative catalyst for some biological functions [30]. Biologically, catalase is found to have potential therapeutic effectiveness against influenza-induced pneumonia [31]. PRKCB, an important regulator of B cells, can regulate metabolic and mitochondrial reprogramming responsible for B cell fate [32]. Some evidence indicates that PRKCB overexpression is associated with the development of pneumonia via activation of the NF-κB pathway [33]. Collectively, these predictive peptides may be used as potential markers for detecting SARS-CoV-2 and may serve as pharmacological targets against SARS-CoV. In further bioinformatics and computational assays, the therapeutic mechanisms of VA for managing COVID-19 could be conjunctively actualized through collective regulation of the FoxO signaling pathway, GnRH signaling pathway, PD-L1 expression, and PD-1 checkpoint pathway. Accordingly, VA demonstrates several pharmacological mechanisms against SARS-CoV, namely, cytoprotective action, anti-viral activity, anti-inflammatory effects, and immunity-based immunomodulation. The anti-coronavirus benefits may be the dual efficacy of a nutrient agent and bioactive compound to treat complex disease by synergistically modulating all presumptive multi-targets and multi-pathways. Adjuvant supplementation of VA may enhance the therapeutic efficacy of current clinical anti-viral agents and immunotherapy to treat potentially fatal COVID-19. However, the current findings should be further validated clinically.

In conclusion, the bioinformatics and computational findings from this study highlight the role of vitamin A in anti-viral, anti-inflammatory, and immunomodulatory effects via different biological processes and cell signaling pathways, as revealed by network pharmacology analysis. More importantly, VA may be used clinically for the treatment of COVID-19, as evidenced by the identified biological processes—which indicate pharmacological functions—and the signaling pathways, which suggest therapeutic mechanisms (Figure 6).

MATERIALS AND METHODS

Identification of candidate genes activated by VA

By using online datasets, in particular TCMSP, Drugbank, SuperPred, Swiss Target Prediction, ChemMapper, and BATMAN TCM, all target genes activated by VA were obtained. The genes activated by VA were collected for target correction from reviewed (Swiss-Prot) and Uniprot databases. The Genecard and OMIM datasets were employed to harvest SARS-CoV-2 genes. All the shortlisted genes and targets of VA and SARS-CoV-2 were subjected to intersection analysis via an online platform with graphical output (http://bioinformatics.psb.ugent.be/webtools/Venn/) in the form of Venn diagrams were plotted to display the relational VA-activated genes and targets of VA against SARS-CoV-2 [34, 35].

Gene Ontology (GO) and KEGG pathway enrichment analyses

The R-language package ClusterProfiler, ReactomePA, org.Hs.eg.Db, and GOplot were applied in the assay and visualization of the relational targets. GO analysis was conducted with the use of org.Hs.eg.Db, with a p-value cutoff of 0.05 in enriched output of bubble charts and Circos-circle charts. The Pathview package in R-language was used to merge the relational targets of enriched KEGG pathways by drawing pathway diagrams [36, 37].

Construction of network visualization in core targets

The software Cytoscape (v3.7.1) was used to plot the component-target-pathway network and the GO biological process and KEGG pathway- based visual graphics of VA against SARS-CoV-2 [38, 39].

Establishment of the biological process and KEGG molecular pathway of VA

To compare the anti-SARS-CoV-2 effects of VA, bioinformatics data of top biological functions and KEGG-enriched pathways were applied for pairwise comparison, including the value of -log10 (p-adjust) as the heat-map parameter, and the heat-map was drawn using HemI 1.0 software [19, 40].

Construction of construction of protein-protein interaction (PPI) network graphics of core targets

The relational targets of VA against SARS-CoV were employed as inputs to the software STRING for plotting target-to-target network interactions and target interaction PPI network diagram. The NetworkAnalyzer setting in Cytoscape software was applied to analyze topology parameters, such as median degrees of freedom and maximum degrees of freedom in the network. The optimal targets were collected based on degree values (DV). The upper limit of the filtering range was the maximum DV in the topology data, and the lower limit was twice the median of freedom, as previously reported [41, 42].
Abbreviations

CAT: Catalase; EGFR: Epidermal growth factor receptor; ICAM1: Intercellular Adhesion Molecule 1; IL10: Interleukin 10; KEGG: Kyoto Encyclopedia of Genes and Genomes; MAPK1: Mitogen-Activated Protein Kinase 1; MAPK14: Mitogen-activated protein kinase 14; OMIM: Online Mendelian Inheritance in Man; PRKCB: Protein kinase C beta type; TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

This study was supported by the National Natural Science Foundation of China (No. 81560134) and the National Natural Science Foundation of Guangxi (No. 2019GXNSFBA185015; 2018GXNSFAA281153). Keng Po Lai was supported by Hong Kong SAR, Macao SAR, and the Taiwan Province Talent Young Scientist Program of Guangxi.

REFERENCES

1. Rubin EJ, Baden LR, Morrissey S. Audio interview: lessons from covid-19 hotspots. N Engl J Med. 2020; 382:e35. https://doi.org/10.1056/NEJMe2007783 PMID:32242382
2. Kaplan EH. Containing 2019-nCoV (Wuhan) coronavirus. Health Care Manag Sci. 2020; 23:311–14. https://doi.org/10.1007/s10729-020-09504-6 PMID:32146554
3. Chu DK, Pan Y, Cheng SM, Hui KP, Krishnan P, Liu Y, Ng DY, Wan CK, Yang P, Wang Q, Peiris M, Poon LL. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem. 2020; 66:549–55. https://doi.org/10.1093/clinchem/hvaa029 PMID:32031583
4. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426:450–54. https://doi.org/10.1038/nature02145 PMID:14647384
5. Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020; 6:11. https://doi.org/10.1038/s41421-020-0147-1 PMID:32133153
6. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res. 2020; 21:74. https://doi.org/10.1186/s12931-020-01338-8 PMID:32216803
7. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020; 14:69–71. https://doi.org/10.5582/bst.2020.01020 PMID:31996494
8. Spinas E, Saggini A, Kritas SK, Cerulli G, Caraffa A, Antinolfi P, Pantalone A, Frydas A, Tei M, Speziali A, Saggini R, Pandolfi F, Conti P. Can vitamin a mediate immunity and inflammation? J Biol Regul Homeost Agents. 2015; 29:1–6. PMID:25864736
9. Soares MM, Silva MA, Garcia PP, Silva LS, Costa GD, Araújo RM, Cotta RM. Efect of vitamin a suplementation: a systematic review. Cien Saude Colet. 2019; 24:827–38. https://doi.org/10.1590/1413-81232018243.07112017 PMID:30892504
10. Ang A, Pullar JM, Currie MJ, Vissers MC. Vitamin C and immune cell function in inflammation and cancer. Biochem Soc Trans. 2018; 46:1147–59. https://doi.org/10.1042/BST20180169 PMID:30301842
11. Stephensen CB. Vitamin A, infection, and immune function. Annu Rev Nutr. 2001; 21:167–92. https://doi.org/10.1146/annurev.nutr.21.1.167 PMID:11375434
12. Lee H, Ko G. New perspectives regarding the antiviral effect of vitamin a on norovirus using modulation of gut microbiota. Gut Microbes. 2017; 8:616–20. https://doi.org/10.1080/19490976.2017.1353842 PMID:28727498
13. Zhang P, Cui TT, Zhang ZH, Wang YQ. Low-dose vitamin a therapy on T lymphocyte function in neonatal pneumonia. Eur Rev Med Pharmacol Sci. 2018; 22:4371–74. https://doi.org/10.26355/eurrev_201807_15437 PMID:30024627
14. Tian Y, Tian Q, Wu Y, Peng X, Chen Y, Li Q, Zhang G, Tian X, Ren L, Luo Z. Vitamin a supplement after neonatal streptococcus pneumoniae pneumonia inhibits the progression of experimental asthma by altering CD4+T cell subsets. Sci Rep. 2020; 10:4214.
15. Xing Y, Sheng K, Xiao X, Li J, Wei H, Liu L, Zhou W, Tong X. Vitamin a deficiency is associated with severe Mycoplasma pneumoniae pneumonia in children. Ann Transl Med. 2020; 8:120. https://doi.org/10.21037/atm.2020.02.33 PMID:32144294

16. Hu N, Li QB, Zou SY. [Effect of vitamin a as an adjuvant therapy for pneumonia in children: a meta analysis]. Zhongguo Dang Dai Er Ke Za Zhi. 2018; 20:146–53. PMID:29429465

17. Ji D, Juhas M, Tsang CM, Kwok CK, Li Y, Zhang Y. Discovery of g-quadruplex-forming sequences in SARS-CoV-2. Brief Bioinform. 2020. [Epub ahead of print]. https://doi.org/10.1093/bib/bbaa114 PMID:32484220

18. AmirJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: a systematic review. Int Immunopharmacol. 2020; 83:106455. https://doi.org/10.1016/j.intimp.2020.106455 PMID:32272396

19. Li R, Wu K, Li Y, Liang X, Lai KP, Chen J. Integrative pharmacological mechanism of vitamin C combined with glycurrhic acid against COVID-19: findings of bioinformatics analyses. Brief Bioinform. 2020. [Epub ahead of print]. https://doi.org/10.1093/bib/bbaa141 PMID:32662814

20. Braicu C, Buse M, Busuicioc C, Drula R, Gulei D, Raduly L, Rusu A, Irimie A, Atanasov AG, Slaby O, Ionescu C, Berindan-Neagoe I. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers (Basel). 2019; 11:1618. https://doi.org/10.3390/cancers11101618 PMID:31652660

21. Dai J, Gu L, Su Y, Wang Q, Zhao Y, Chen X, Deng H, Li W, Wang G, Li K. Inhibition of curcumin on influenza a virus infection and influenza pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-kB pathways. Int Immunopharmacol. 2018; 54:177–87. https://doi.org/10.1016/j.intimp.2017.11.009 PMID:29153953

22. Sabbah DA, Hajo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 2020; 20:815–34. https://doi.org/10.2174/1568026620666200303123102 PMID:32124699

23. Choi WI, Jeong J, Lee CW. Association between EGFR mutation and ageing, history of pneumonia and gastroesophageal reflux disease among patients with advanced lung cancer. Eur J Cancer. 2019; 122:101–08. https://doi.org/10.1016/j.ejca.2019.09.010 PMID:31634646

24. Fang D, Zhu J. Molecular switches for regulating the differentiation of inflammatory and IL-10-producing anti-inflammatory t-helper cells. Cell Mol Life Sci. 2020; 77:289–303. https://doi.org/10.1007/s00018-019-03277-0 PMID:31432236

25. Ding S, Wang X, Chen W, Fang Y, Liu B, Liu Y, Fei G, Wang L. Decreased interleukin-10 responses in children with severe mycoplasma pneumoniae pneumonia. PLoS One. 2016; 11:e0146397. https://doi.org/10.1371/journal.pone.0146397 PMID:26751073

26. Chakraborty K, Raundhal M, Chen BB, Morse C, Tyurina YY, Khare A, Oriss TB, Huff R, Lee JS, St Croix CM, Watkins S, Mallampalli RK, Kagan VE, et al. The mito-DAMP cardiolipin blocks IL-10 production causing persistent inflammation during bacterial pneumonia. Nat Commun. 2017; 8:13944. https://doi.org/10.1038/ncomms13944 PMID:28074841

27. Mukhopadhay S, Malik P, Arora SK, Mukherjee TK. Intercellular adhesion molecule-1 as a drug target in asthma and rhinitis. Respiriology. 2014; 19:508–13. https://doi.org/10.1111/resp.12285 PMID:24689994

28. Abo-Hagar HH, Abo-Elezz AA, Mehrez M, Mabrouk MM, Elshora OA. Diagnostic efficacy of serum amyloid a protein and soluble intercellular adhesion molecule 1 in pediatric ventilator-associated pneumonia. J Intensive Care Med. 2019; 34:503–10. https://doi.org/10.1177/0885066617702598 PMID:28403662

29. Chang PY, Tsao SM, Chang JH, Chen MH, Hung WY, Huang YW, Yang SF. Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia. Clin Chim Acta. 2016; 463:174–80. https://doi.org/10.1016/j.cca.2016.10.030 PMID:27983998

30. Glorieux C, Calderon PB. Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach. Biol Chem. 2017; 398:1095–108. https://doi.org/10.1515/hsz-2017-0131 PMID:28384098

31. Shi X, Shi Z, Huang H, Zhu H, Zhu H, Ju D, Zhou P. PEGylated human catalase elicits potent therapeutic effects on H1N1 influenza-induced pneumonia in mice. Appl Microbiol Biotechnol. 2013; 97:10025–33. https://doi.org/10.1007/s00253-013-4775-3 PMID:23525936
32. Tsui C, Martinez-Martin N, Gaya M, Maldonado P, Llorian M, Legrave NM, Rossi M, MacRae JI, Cameron AJ, Parker PJ, Leitges M, Bruckbauer A, Batista FD. Protein kinase c-β dictates B cell fate by regulating mitochondrial remodeling, metabolic reprogramming, and heme biosynthesis. Immunity. 2018; 48:1144–59.e5. https://doi.org/10.1016/j.immuni.2018.04.031 PMID: 29884460

33. Vielma SA, Krings G, Lopes-Virella MF. Chlamydia pneumoniae induces ICAM-1 expression in human aortic endothelial cells via protein kinase c-dependent activation of nuclear factor-kappaB. Circ Res. 2003; 92:1130–37. https://doi.org/10.1161/01.RES.0000074001.46892.1C PMID: 12714566

34. Su M, Guo C, Liu M, Liang X, Yang B. Therapeutic targets of vitamin C on liver injury and associated biological mechanisms: a study of network pharmacology. Int Immunopharmacol. 2019; 66:383–87. https://doi.org/10.1016/j.intimp.2018.11.048 PMID: 30530052

35. Wu K, Wei P, Liu M, Liang X, Su M. To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis. J Adv Res. 2019; 20:43–50. https://doi.org/10.1016/j.jare.2019.05.003 PMID: 31193808

36. Zhou R, Wu K, Su M, Li R. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma. Environ Toxicol Pharmacol. 2019; 70:103200. https://doi.org/10.1016/j.etap.2019.103200 PMID: 31158732

37. Li R, Guo C, Li Y, Qin Z, Huang W. Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study. Brief Bioinform. 2020. [Epub ahead of print].

38. Li R, Guo C, Li Y, Liang X, Yang L, Huang W. Therapeutic target and molecular mechanism of vitamin c-treated pneumonia: a systematic study of network pharmacology. Food Funct. 2020; 11:4765–72. https://doi.org/10.1039/d0fo00421a PMID: 32420559

39. Li R, Song Y, Ji Z, Li L, Zhou L. Pharmacological biotargets and the molecular mechanisms of oxyresveratrol treating colorectal cancer: network and experimental analyses. Biofactors. 2020; 46:158–67. https://doi.org/10.1002/biof.1583 PMID: 31647596

40. Li R, Ma X, Song Y, Zhang Y, Xiong W, Li L, Zhou L. Anti-colorectal cancer targets of resveratrol and biological molecular mechanism: analyses of network pharmacology, human and experimental data. J Cell Biochem. 2019. [Epub ahead of print]. https://doi.org/10.1002/jcb.28404 PMID: 30719773

41. Ge B, Guo C, Liang Y, Liu M, Wu K. Network analysis, and human and animal studies disclose the anti-cystitis glandularis effects of vitamin C. Biofactors. 2019; 45:912–19. https://doi.org/10.1002/biof.1558 PMID: 31469455

42. Liang Y, Zhou R, Liang X, Kong X, Yang B. Pharmacological targets and molecular mechanisms of plumbagin to treat colorectal cancer: a systematic pharmacology study. Eur J Pharmacol. 2020; 881:173227. https://doi.org/10.1016/j.ejphar.2020.173227 PMID: 32505664
SUPPLEMENTARY MATERIALS

Supplementary Tables

Please browse Full Text version to see the data of Supplementary Table 1.

Supplementary Table 1. Gene ontology analysis (biological process) using the identified seven core targets of VA against SARS-CoV-2.

| ID   | Description                                                      | GeneRatio | BgRatio | pvalue     | p.adjust  | qvalue    | geneID                  | Count | remark   |
|------|------------------------------------------------------------------|-----------|---------|------------|------------|-----------|--------------------------|-------|----------|
| hsa05163 | Human cytomegalovirus infection                                  | 4/7       | 225/8025| 1.97E-05   | 0.000313   | 8.71E-05 | MAPK1/EGFR/ MAPK14/PRKCB | 4     | viral    |
| hsa05164 | Influenza A                                                      | 3/7       | 170/8025| 0.00030    | 0.00132    | 0.000367 | MAPK1/ICAM1 /PRKCB       | 3     | viral    |
| hsa05167 | Kaposi sarcoma-associated herpesvirus infection                 | 3/7       | 186/8025| 0.0004     | 0.001632   | 0.000454 | MAPK1/ICAM1 /MAPK14      | 3     | viral    |
| hsa05170 | Human immunodeficiency virus 1 infection                        | 3/7       | 212/8025| 0.00058    | 0.002175   | 0.000605 | MAPK1/MAPK14/PRKCB       | 3     | viral    |
| hsa05160 | Hepatitis C                                                      | 2/7       | 155/8025| 0.00730    | 0.012354   | 0.003435 | MAPK1/EGFR               | 2     | viral    |
| hsa05169 | Epstein-Barr virus infection                                    | 2/7       | 201/8025| 0.01206    | 0.019176   | 0.005332 | ICAM1/MAPK14             | 2     | viral    |
| hsa05165 | Human papillomavirus infection                                  | 2/7       | 330/8025| 0.03086    | 0.045444   | 0.012636 | MAPK1/EGFR               | 2     | viral    |
| hsa04660 | T cell receptor signaling pathway                               | 3/7       | 104/8025| 7.13E-05   | 0.000515   | 0.000143 | MAPK1/IL10/MAPK14        | 3     | immune   |
| hsa04670 | Leukocyte transendothelial migration                            | 3/7       | 112/8025| 8.89E-05   | 0.000524   | 0.000146 | ICAM1/MAPK14/PRKCB       | 3     | immune   |
| hsa04650 | Natural killer cell mediated cytotoxicity                       | 3/7       | 131/8025| 0.00014    | 0.000705   | 0.000196 | MAPK1/ICAM1/PRKCB        | 3     | immune   |
| hsa04664 | Fc epsilon RI signaling pathway                                 | 2/7       | 68/8025 | 0.00144    | 0.00442    | 0.001229 | MAPK1/MAPK14             | 2     | immune   |
| hsa04662 | B cell receptor signaling pathway                               | 2/7       | 82/8025 | 0.00209    | 0.005552   | 0.001544 | MAPK1/PRKCB              | 2     | immune   |
| hsa04658 | Th1 and Th2 cell differentiation                                | 2/7       | 92/8025 | 0.00263    | 0.006744   | 0.001875 | MAPK1/PRKCB              | 2     | immune   |
| hsa04666 | Fc gamma R-mediated phagocytosis                                | 2/7       | 93/8025 | 0.00268    | 0.00678    | 0.001885 | MAPK1/PRKCB              | 2     | immune   |
| hsa04657 | IL-17 signaling pathway                                         | 2/7       | 94/8025 | 0.00274    | 0.006817   | 0.001895 | MAPK1/PRKCB              | 2     | immune   |
| hsa04620 | Toll-like receptor signaling pathway                            | 2/7       | 104/8025| 0.00334    | 0.007293   | 0.002028 | MAPK1/PRKCB              | 2     | immune   |
| hsa04659 | Th17 cell differentiation                                       | 2/7       | 107/8025| 0.00354    | 0.007608   | 0.002115 | MAPK1/PRKCB              | 2     | immune   |

Supplementary Table 2. KEGG pathway enrichment analysis using the identified seven core targets of VA against SARS-CoV-2.

| ID   | Description                                                      | GeneRatio | BgRatio | pvalue     | p.adjust  | qvalue    | geneID                  | Count | remark   |
|------|------------------------------------------------------------------|-----------|---------|------------|------------|-----------|--------------------------|-------|----------|
| hsa04660 | T cell receptor signaling pathway                               | 3/7       | 104/8025| 7.13E-05   | 0.000515   | 0.000143 | MAPK1/IL10/MAPK14        | 3     | immune   |
| hsa04670 | Leukocyte transendothelial migration                            | 3/7       | 112/8025| 8.89E-05   | 0.000524   | 0.000146 | ICAM1/MAPK14/PRKCB       | 3     | immune   |
| hsa04650 | Natural killer cell mediated cytotoxicity                       | 3/7       | 131/8025| 0.00014    | 0.000705   | 0.000196 | MAPK1/ICAM1/PRKCB        | 3     | immune   |
| hsa04664 | Fc epsilon RI signaling pathway                                 | 2/7       | 68/8025 | 0.00144    | 0.00442    | 0.001229 | MAPK1/MAPK14             | 2     | immune   |
| hsa04662 | B cell receptor signaling pathway                               | 2/7       | 82/8025 | 0.00209    | 0.005552   | 0.001544 | MAPK1/PRKCB              | 2     | immune   |
| hsa04658 | Th1 and Th2 cell differentiation                                | 2/7       | 92/8025 | 0.00263    | 0.006744   | 0.001875 | MAPK1/PRKCB              | 2     | immune   |
| hsa04666 | Fc gamma R-mediated phagocytosis                                | 2/7       | 93/8025 | 0.00268    | 0.00678    | 0.001885 | MAPK1/PRKCB              | 2     | immune   |
| hsa04657 | IL-17 signaling pathway                                         | 2/7       | 94/8025 | 0.00274    | 0.006817   | 0.001895 | MAPK1/PRKCB              | 2     | immune   |
| hsa04620 | Toll-like receptor signaling pathway                            | 2/7       | 104/8025| 0.00334    | 0.007293   | 0.002028 | MAPK1/PRKCB              | 2     | immune   |
| hsa04659 | Th17 cell differentiation                                       | 2/7       | 107/8025| 0.00354    | 0.007608   | 0.002115 | MAPK1/PRKCB              | 2     | immune   |
| ID   | Pathway                                      | Detail                                                                 | Annotation |
|------|----------------------------------------------|------------------------------------------------------------------------|------------|
| hsa04 750 | Human T-cell leukemia virus 1 infection      | Inflammatory mediator regulation of TRP channels                       | immune     |
| hsa04 621 | NOD-like receptor signaling pathway          | Chemokine signaling pathway                                            | drug       |
| hsa04 062 |        |                                          |                          |            |
| hsa04 068 | FoxO signaling pathway                       |                                                                         | signaling   |
| hsa04 370 | VEGF signaling pathway                       |                                                                         | signaling   |
| hsa04 668 | TNF signaling pathway                        |                                                                         | signaling   |
| hsa04 014 | Ras signaling pathway                        |                                                                         | signaling   |
| hsa04 064 | NF-kappa B signaling pathway                 |                                                                         | signaling   |
| hsa04 072 | Phospholipase D signaling pathway            |                                                                         | signaling   |
| hsa04 150 | mTOR signaling pathway                       |                                                                         | signaling   |
| hsa04 630 | JAK-STAT signaling pathway                  |                                                                         | signaling   |

**Annotate the pathways based on their biological contexts:**

- **Immune Response:** Human T-cell leukemia virus 1 infection
- **Inflammation:** NOD-like receptor signaling pathway
- **Drug Targeting:** Chemokine signaling pathway
- **Signaling Pathways:**
  - FoxO signaling pathway
  - VEGF signaling pathway
  - TNF signaling pathway
  - Ras signaling pathway
  - NF-kappa B signaling pathway
  - Phospholipase D signaling pathway
  - mTOR signaling pathway
  - JAK-STAT signaling pathway